Natco Pharma launches HEPCINAT LP in Nepal

Image
Capital Market
Last Updated : Oct 28 2015 | 12:01 PM IST

Used in treatment chronic hepatitis C

Natco Pharma announced that it has launched the first licensed generic version of ledipasvir + sofosbuvir combination of Nepal, under its brand name Hepcinat LP.

Ledipasvir + Sofosbuvir is a two drug fixed-dose combination product that contains 90 mg of ledipasvir and 400 mg of sofosbuvir in a single tablet, and sold globally by Gilead Sciences Inc. under its brand HARVONI. It is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. NATCO priced generic medicine, Hepcinat LP, at an MRP of INR 25,000 for a bottle of 28 tablets in Nepal.

Powered by Capital Market - Live News

More From This Section

First Published: Oct 28 2015 | 10:55 AM IST

Next Story